Bicocca Open Archive

Logo unimib boa
RIZZARI, CARMELO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.663
EU - Europa 2.543
AS - Asia 1.023
SA - Sud America 7
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 3
Totale 9.250
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.563
IE - Irlanda 479
SE - Svezia 458
IT - Italia 437
SG - Singapore 412
RU - Federazione Russa 359
CN - Cina 293
DE - Germania 270
HK - Hong Kong 208
UA - Ucraina 183
GB - Regno Unito 99
CA - Canada 78
FI - Finlandia 58
AT - Austria 51
FR - Francia 51
VN - Vietnam 36
IN - India 23
TR - Turchia 20
DK - Danimarca 19
NL - Olanda 18
BE - Belgio 11
HN - Honduras 11
ID - Indonesia 11
CZ - Repubblica Ceca 10
BZ - Belize 8
ES - Italia 7
AU - Australia 6
BG - Bulgaria 5
GR - Grecia 5
IR - Iran 5
BR - Brasile 4
CH - Svizzera 4
EU - Europa 4
JP - Giappone 4
PL - Polonia 4
PT - Portogallo 4
PE - Perù 3
RS - Serbia 3
TH - Thailandia 3
BA - Bosnia-Erzegovina 2
BD - Bangladesh 2
EG - Egitto 2
MX - Messico 2
NO - Norvegia 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
IL - Israele 1
KH - Cambogia 1
KR - Corea 1
LV - Lettonia 1
PH - Filippine 1
PK - Pakistan 1
RO - Romania 1
ZA - Sudafrica 1
Totale 9.250
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.254
Fairfield 484
Woodbridge 477
Dublin 452
Chandler 387
Singapore 368
Ashburn 281
Houston 279
Wilmington 259
Frankfurt am Main 215
New York 204
Hong Kong 203
Jacksonville 191
Cambridge 183
Princeton 176
Seattle 174
Milan 114
Dearborn 110
Santa Clara 93
Lawrence 88
Altamura 75
San Diego 53
Beijing 51
Vienna 51
Nanjing 48
Shanghai 44
Lachine 31
Boardman 29
Buffalo 28
Toronto 24
Helsinki 23
Andover 22
London 22
Guangzhou 21
Lissone 18
Falls Church 17
Rome 17
Los Angeles 14
Shenyang 14
Hebei 13
Norwalk 13
Ottawa 13
Changsha 12
Chicago 12
Hangzhou 11
Huizen 11
Jakarta 11
Jinan 11
Redmond 11
Tegucigalpa 11
Jiaxing 10
Moscow 10
Nanchang 10
Brussels 9
Casper 9
Kocaeli 9
Belize City 8
Mountain View 8
Munich 8
Turin 8
Zhengzhou 8
Perugia 7
San Mateo 7
Washington 7
Dong Ket 6
Leawood 6
Olomouc 6
Tianjin 6
Florence 5
Grafing 5
Monza 5
Paris 5
Athens 4
Bologna 4
Clifton 4
Hefei 4
Kardzhali 4
Lisbon 4
Naples 4
Adelaide 3
Bangkok 3
Brno 3
Catania 3
Edmonton 3
Gaithersburg 3
Gap 3
Kilburn 3
Kunming 3
Lima 3
Ningbo 3
Philadelphia 3
Pune 3
Ravenna 3
San Bernardino 3
Siena 3
University Park 3
Willowdale 3
Americana 2
Amsterdam 2
Ancona 2
Totale 6.973
Salva come PNG Salva come JPEG
Nome #
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 313
Acute myeloid leukaemia niche regulates response to L-asparaginase 309
ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells 253
Reduced-Intensity delayed intensification in standard-Risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000) 235
Children with cancer in the time of COVID-19: An 8-week report from the six pediatric onco-hematology centers in Lombardia, Italy 235
Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study 221
A novel EP300 mutation associated with Rubinstein-Taybi syndrome type 2 presenting as combined immunodeficiency 221
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 192
Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations 187
Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study 175
Lessons after the early management of the COVID-19 outbreak in a pediatric transplant and hemato-oncology center embedded within a COVID-19 dedicated hospital in Lombardia, Italy. Estote parati 175
Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica 163
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 163
Constitutional and somatic deletions of the Williams-Beuren syndrome critical region in non-Hodgkin lymphoma 163
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 162
Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica 162
Early T-cell precursor acute lymphoblastic leukaemia in children treated in AIEOP centres with AIEOP-BFM protocols: A retrospective analysis 158
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 154
Outcome of very late relapse in children with acute lymphoblastic leukemia 152
Prognostic value of nephromegaly at diagnosis of childhood acute lymphoblastic leukemia 152
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 151
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 150
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 149
Screening for Coagulopathy and Identification of Children With Acute Lymphoblastic Leukemia at a Higher Risk of Symptomatic Venous Thrombosis: An AIEOP Experience 145
FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia 145
Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy 140
Hermansky-Pudlak syndrome type II and lethal hemophagocytic lymphohistiocytosis: Case description and review of the literature 140
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 138
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment 137
MTHFR 677C-->T mutation and neural-tube defects 126
Williams syndrome and mature B-Leukemia: A random association? 126
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 126
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995 125
Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia 123
Are genotypes of glutathione S-transferase superfamily a risk factor for childhood acute lymphoblastic leukemia? Results of an Italian case-control study 120
Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups 120
Treatment reduction in highly selected standard-risk childhood acute lymphoblastic leukemia. The AIEOP ALL-9501 study 119
Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica 118
Ischemic stroke in children treated for acute lymphoblastic leukemia: a retrospective study 116
Role of DNA index in childhood acute lymphoblastic leukemia treated with BFM based therapy: Long term results of the AIEOP-ALL 95 115
Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia 106
Genotypes of the glutathione S-transferase superfamily do not correlate with outcome of childhood acute lymphoblastic leukemia 106
A Case of T-cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia 106
Outcome of adolescent patients with acute lymphoblastic leukaemia aged 10–14 years as compared with those aged 15–17 years: Long-term results of 1094 patients of the AIEOP-BFM ALL 2000 study 106
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia 105
Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies 103
Mucopolysaccharidosis-Plus Syndrome, a Rapidly Progressive Disease: Favorable Impact of a Very Prolonged Steroid Treatment on the Clinical Course in a Child 95
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 94
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II 93
Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study 93
Correspondence: Osteonecrosis in childhood acute lymphoblastic leukemia: a retrospective cohort study of the Italian Association of Pediatric Haemato-Oncology (AIEOP) 89
Favorable Outcome of Children with Acute Megakaryoblastic Leukemia Treated with the AIEOP AML 2002/01 Protocol 88
A boy with Burkitt lymphoma associated with Noonan syndrome due to a mutation in RAF1 87
Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia 86
Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL 84
Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias 63
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia 62
Osteonecrosis in paediatric acute lymphoblastic leukaemia: Incidence, risk factors, radiological patterns and evolution in a single-centre cohort 61
Nationwide central diagnosis review for childhood solid tumors: From concept to realization of an Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) integrated project 54
A three-miRNA-based expression signature at diagnosis can predict occurrence of relapse in children with t(8;21) RUNX1-RUNX1T1 acute myeloid leukaemia 51
Legionellosis in paediatrics [Legionellosi in pediatria] 51
Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children with Influenza 47
Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol 44
Effect of Blinatumomab vs Chemotherapy on Event-Free Survival among Children with High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial 44
FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD) 42
Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data 41
A phase 1/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia 39
Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia 39
Phase I/Phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia 38
Impact of COVID-19 in paediatric early-phase cancer clinical trials in Europe: A report from the Innovative Therapies for Children with Cancer (ITCC) consortium 38
Asparaginase pharmacokinetics and implications of therapeutic drug monitoring 37
Road Traffic Pollution and Childhood Leukemia: A Nationwide Case-control Study in Italy 37
Can recombinant technology address asparaginase Erwinia chrysanthemi shortages? 36
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation 35
Biological therapies in monogenic autoinflammatory diseases: Long-term efficacy and safety 34
Hypersensitivity Reactions to Native E. coli L-asparaginase in Children with Acute Lymphoblastic Leukemia Treated in Trial ALL-BFM 2000: Impact of Treatment Schedule and Type of Glucocorticoid in Induction 34
A phase 2 study of nilotinib in pediatric patients with CML: Long-term update on growth retardation and safety 33
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children with Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol 32
Still trying to pick the best asparaginase preparation 32
Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study 32
Human Fibrinogen Concentrate and Fresh Frozen Plasma in the Management of Severe Acquired Hypofibrinogenemia in Children with Acute Lymphoblastic Leukemia: Results of a Retrospective Survey 32
Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients — a 25-year Italian experience 32
NUP214–ABL1 fusion in childhood T-ALL 32
ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment 31
Therapeutic drug monitoring of asparaginase activity - Method comparison of MAAT and AHA test used in the international AIEOP-BFM ALL 2009 trial 31
Collaborative efforts driving progress in pediatric acute myeloid leukemia 31
Recommendations by the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA) Working Group on preparedness of clinical trials about paediatric medicines process 31
CD56, HLA-DR, and CD45 recognize a subtype of childhood AML harboring CBFA2T3-GLIS2 fusion transcript 31
Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA/ATO 30
Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): Summary of an expert panel discussion 30
Outcome of children with acute myeloid leukaemia (AML) experiencing primary induction failure in the AIEOP AML 2002/01 clinical trial 30
Minimal residual disease monitored after induction therapy by rq-pcr can contribute to tailor treatment of patients with t(8;21) runx1-runx1t1 rearrangement 30
Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study 28
Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product 28
Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL 27
Emapalumab in children with primary hemophagocytic lymphohistiocytosis 27
Pharmacokinetics of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia or acute lymphoblastic leukemia 27
Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing 25
Inotuzumab ozogamicin in older patients with acute lymphoblastic leukaemia: premises and promises 23
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational Campus ALL study 22
Totale 9.649
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.673
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.673
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020996 0 0 0 115 129 148 164 98 127 89 96 30
2020/20211.539 76 51 130 141 147 243 136 150 98 163 97 107
2021/20221.311 85 99 105 164 141 135 53 67 106 81 71 204
2022/20231.712 247 528 95 149 112 278 18 82 117 16 44 26
2023/20241.355 83 33 58 69 168 353 275 32 117 22 18 127
2024/2025999 182 509 210 98 0 0 0 0 0 0 0 0
Totale 9.790